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Abstract
The ability to effectively measure health-related quality-of-life longitudinally is central to describing
the impacts of disease, treatment, or other insults, including normal aging, upon the patient. Over
the last two decades, assessment of patient health status has undergone a dramatic paradigm shift,
evolving from a predominant reliance on biochemical and physical measurements, such as
erythrocyte sedimentation rate, lipid profiles, or radiographs, to an emphasis upon health
outcomes based on the patient's personal appreciation of their illness. The Health Assessment
Questionnaire (HAQ), published in 1980, was among the first instruments based on generic,
patient-centered dimensions. The HAQ was designed to represent a model of patient-oriented
outcome assessment and has played a major role in many diverse areas such as prediction of
successful aging, inversion of the therapeutic pyramid in rheumatoid arthritis (RA), quantification
of NSAID gastropathy, development of risk factor models for osteoarthrosis, and examination of
mortality risks in RA.
Evidenced by its use over the past two decades in diverse settings, the HAQ has established itself
as a valuable, effective, and sensitive tool for measurement of health status. It is available in more
than 60 languages and is supported by a bibliography of more than 500 references. It has increased
the credibility and use of validated self-report measurement techniques as a quantifiable set of hard
data endpoints and has contributed to a new appreciation of outcome assessment. In this article,
information regarding the HAQ's development, content, dissemination and reference sources for
its uses, translations, and validations are provided.
Why assess Health-Related Quality of Life with 
the Health Assessment Questionnaire (HAQ)?
The ability to effectively measure health-related quality-
of-life longitudinally is central to describing the impacts
of disease, treatment, or other insults, including normal
aging, upon the patient. Assessing these outcomes
requires instruments that are comprehensive, reliable,
valid, responsive, and those that have been stable for a
sufficient length of time to permit longitudinal study.
Such measures are particularly significant in studies where
short term results are not the primary outcomes of inter-
est, but can be of use over periods as short as six weeks.
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The HAQ is one of the most widely used comprehensive,
validated, patient-oriented outcome assessment instru-
ments. It has been administered by the Stanford Arthritis,
Rheumatism, and Aging Medical Information System
(ARAMIS) more than 200,000 times to assess clinical sta-
tus, evaluate effectiveness in clinical and observational tri-
als, and to define health outcomes, and it is sanctioned by
the American College of Rheumatology for assessing
physical function in rheumatoid arthritis trials[1,2]. It is
available in more than 60 languages and is supported by
a bibliography of more than 500 references.
What is the HAQ?
The HAQ is one of the first instruments deliberately
designed to capture prospectively and by protocol the
long term influence of multiple chronic illnesses and to
allow supplementation by additional measures for partic-
ular studies. The HAQ has played an influential role in
establishing health outcome assessment as a quantifiable
set of reliable, valid and responsive hard data points.
Because the HAQ emanated from the rheumatology field,
it sometimes has been characterized as a "disease-specific"
instrument rather than having been adjudicated on the
basis of its structure, content, and history of use. The HAQ
has been and continues to be administered across diverse
disciplines and in different cultures, with properly
designed adaptations that do not impact its reliability and
validity. It should be considered a "generic" rather than a
"disease-specific" instrument, since it assesses the dimen-
sions of death, disability, drug side effects, discomfort,
and economic costs, none of which are "disease-specific".
What areas of health does the HAQ measure?
The HAQ is typically used in one of two formats. The full
HAQ collects data on five generic patient-centered health
dimensions: (1) to avoid disability; (2) to be free of pain
and discomfort; (3) to avoid adverse treatment effects; (4)
to keep dollar costs of treatment low; and (5) to postpone
death [3–6]. It includes sections on drug side effects and
medical costs, as well as supplemental sections on demo-
graphics, lifestyle and health behaviors. However, the ver-
sion that has received the widest attention, most frequent
use, and what is commonly referred to in the literature as
"the HAQ," is the "short" or "2-page" HAQ. The 2-page
HAQ contains the HAQ Disability Index (HAQ-DI), the
HAQ visual analog (VAS) pain scale, and the VAS patient
global health scale; [see Additional file: 1 HAQ Question-
naire.pdf for a copy of the English version of the
questionnaire].
As with any instrument, the HAQ has limitations, and as
generally used, does not capture disability associated with
sensory organ dysfunction or psychiatric dysfunction and
does not directly measure patient satisfaction or social
networking. Yet these variables, or other variables of inter-
est to the user, can be readily appended.
The HAQ Disability Index (HAQ-DI). The disability assess-
ment component of the HAQ, the HAQ-DI, assesses a
patient's level of functional ability and includes questions
of fine movements of the upper extremity, locomotor
activities of the lower extremity, and activities that involve
both upper and lower extremities. There are 20 questions
in eight categories of functioning which represent a com-
prehensive set of functional activities – dressing, rising,
eating, walking, hygiene, reach, grip, and usual activities.
The stem of each item asks over the past week "Are you
able to …" perform a particular task. The patient's
responses are made on a scale from zero (no disability) to
three (completely disabled). Each category contains at
least two specific component questions (See Additional
File 1_2-page HAQ Questionnaire.pdf for a copy of the
English version of the HAQ-DI).
The HAQ VAS Pain Scale. The HAQ pain scale is designed
to assess the presence or absence of arthritis-related pain
and its severity. The objective is to obtain information
from patients on how their pain has usually been over the
past week, even though pain may be reported to vary over
the course of a day or from day to day. The HAQ pain scale
consists of a doubly anchored, horizontal VAS, that is
scored from zero (no pain) to three (severe pain), or alter-
natively from 0 (no pain) to 100 (severe pain). The VAS
for pain has been used widely in experimental, observa-
tional, and clinical settings [7–12].
Other Dimensions of the Full HAQ. Drug toxicity data col-
lected by the full HAQ include the drug, dosage, time on
drug, specific side effects, degree of severity, the impor-
tance to the patient, and subsequent drug course, i.e.,
whether or not the drug was discontinued due to the side
effect. HAQ-derived drug side effect data has permitted
the development of a summary Toxicity Index (TI) that
quantifies the magnitude of adverse effects (toxicity) asso-
ciated with specific medications [11,13,14]. The TI is a
first attempt to quantitatively describe the overall toxicity
of medication. Prior adverse effect assessments had used
variables comprised of the percentage of patients discon-
tinuing the drug because of side effects or had presented
comparative frequencies of selected individual side
effects.
Direct cost data that include physician visits, hospital
days, laboratory costs, x-rays, medications, and other
medical costs including use of alternative treatments and
procedures, and indirect cost data due to loss of produc-
tivity are captured by the full HAQ.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/20
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Death, while obviously not a self-report outcome on the
HAQ, is a requisite part of the conceptual model of
patient outcome. In this HAQ dimension, mortality-
related data, causes, and date of death, are obtained via
search of the United States National Death Index.
Both the 2-page and full HAQ contain the HAQ VAS
patient global health status scale. It is among the common
VAS instruments, which include the Torrance "feeling
thermometer" in the EuroQol instrument and the VAS in
the Arthritis Impact Measurement Scales, both of which
are used to measure quality of life. The HAQ global health
status scale is a 15 cm doubly-anchored horizontal VAS
that is scored from zero (very well) to 100 (very poor) and
has been validated as a measure of quality of life. Fries and
Ramey [15] compared the HAQ global to the Torrance
quality-of-life "feeling thermometer" and found the two
scales to be highly correlated (r = -0.676; p < 0.001), indi-
cating that both instruments are measuring similar quality
of life constructs.
How was the HAQ developed?
The Health Assessment Questionnaire (HAQ) was origi-
nally developed in 1978 by James F. Fries, MD, and col-
leagues at Stanford University. The HAQ Disability Index
(HAQ-DI), the original HAQ section to be developed and
validated, was initially developed under the auspices of
the Stanford Arthritis Center. It recognized the impor-
tance of the original American Rheumatism Association
functional class measure [16] and also the lack of sensitiv-
ity to change of that four-category measure. The HAQ-DI
was developed by parsing questions and components
from a variety of instruments extant at the time, and
evolved over numerous iterations through a series of sub-
jective and objective assessments via statistical evaluation,
physician appraisal, and patient feedback [17].
The components of the 2-page HAQ (the HAQ-DI, pain
scale, and global health status scale) have retained their
original content and format since the early 1980s, while
the remaining dimensions in the full HAQ are periodi-
cally tailored and supplemented with additional ques-
tions when contemporary issues arise for specific
hypotheses or research questions by ARAMIS or other
investigators.
How was the HAQ validated?
The disability index of the HAQ (HAQ-DI) has been vali-
dated in numerous studies and disciplines. It has been
shown repeatedly to possess face and content validity via
comparison with other instruments in multiple disease
conditions. The construct/convergent validity, predictive
validity, and sensitivity to change have also been estab-
lished in numerous observational studies and clinical tri-
als. The HAQ-DI has also demonstrated a high level of
convergent validity based on the pattern of correlations
with other clinical and laboratory measures [2,11,17–19].
Validity of the HAQ pain scale and the global health status
scale have also been demonstrated in numerous studies
[2,11].
In which populations has the HAQ been used?
The full HAQ has been deployed in studies with HIV/
AIDS patients, normal aging populations, adults and chil-
dren with rheumatic diseases, and in disabled work-
ers[2,20–22]. It has been employed in population-based
studies, including the follow-up to the National Health
and Nutrition Examination Survey (NHANES) [23]. It has
also been applied to a variety of diseases and conditions,
including osteoarthritis, juvenile rheumatoid arthritis,
systemic lupus erythematosus, ankylosing spondylitis,
fibromyalgia, psoriatic arthritis, systemic sclerosis and has
been adapted in many languages for adults as well as chil-
dren [2].
What translations are available?
The HAQ Disability Index (HAQ-DI) was originally devel-
oped and validated for English-speaking populations in
the United States and Canada. It has since been translated
or culturally adapted into more than 60 different lan-
guages or dialects, often with only minor changes. Table 1
presents a resource listing of translations since 2002.
Translations and cultural adaptations of the HAQ-DI are
usually carried out by administering investigators. Many
have also been performed by the MAPI Research Institute
in Lyon, France, and the Health Outcomes Group in Palo
Alto, California, both of which have had extensive experi-
ence in translating and culturally validating the HAQ-DI;
fees are sometimes charged by these vendors.
Translated HAQ-DIs have generally been fully validated,
using methods such as test-retest reliability, item-total
correlations, convergent validity, interviewer vs. self-
administered formats, and factor analyses. Translations
are subsequently back-translated by a different translator,
and the two English versions compared. This process is
repeated until coherence is achieved. To date, culturally
adapted HAQ-DI instruments have proved as equally reli-
able and valid as their parent. To adapt the HAQ-DI cul-
turally, modifications of individual items have sometimes
been necessary. The types of items most frequently in
need of adaptation have included colloquial expressions
or those for which names or types of items or utensils are
culturally idiosyncratic. For example, some Asian cultures
do not consume milk in cartons; thus, an appropriate sub-
stitution in keeping with the original intent of the item is
made. In some European countries a bathtub is much
more commonly used than is a shower, requiring ques-
tion modification.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/20
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How is the HAQ administered and how long 
does it take?
The HAQ is usually self-administered, but can also be
given face-to-face in a clinical setting or in a telephone
interview format by trained outcome assessors, and has
been validated in all of these settings. The questionnaire is
typically mailed to patients every six months, who are
asked to complete it without additional instructions.
Patients usually find that the 2-page HAQ is entirely self-
explanatory, and clarifications are seldom required. Fol-
low-up phone calls are sometimes needed to obtain miss-
ing data or to clarify ambiguous responses in the high-
quality research data applications. The HAQ disability
index and pain scale can be completed in approximately
five minutes. The full HAQ takes 20 to 30 minutes to
complete.
How is the HAQ Disability Index (HAQ-DI) and 
pain scale scored?
The HAQ-DI indicates the extent of the respondent's func-
tional ability, is sensitive to change, and is a good predic-
tor of future disability and costs. It assesses a patient's
usual abilities using their usual equipment during the past
week. Scoring of the HAQ-DI is patterned after the Amer-
ican Rheumatism Association/American College of Rheu-
matology functional classes [16,24]. For each item, there
is a four-level difficulty scale that is scored from 0 to 3,
representing normal (no difficulty) (0), some difficulty
(1), much difficulty (2), and unable to do (3). There are
20 questions in eight categories of functioning – dressing,
rising, eating, walking, hygiene, reach, grip, and usual
activities. The highest component score in each category
determines the score for the category, unless aids or
devices are required. Dependence on equipment or phys-
ical assistance increases a lower score to the level of 2 to
more accurately represent underlying disability. A com-
plementary scoring method ignores scores for aids and
devices when computing the category scores and repre-
sents residual disability after compensatory efforts. The
eight category scores are averaged into an overall HAQ-DI
score on a scale from zero (no disability) to three (com-
pletely disabled). The scale is not truly continuous but has
25 possible values (i.e., 0, 0.125, 0.250, 0.375 … 3). The
HAQ-DI score is not computed when the patient provides
answers in fewer than six categories. When the HAQ-DI is
used to assess disability in a specific disease or condition,
usually a single word change can be made in the stem to
identify the condition [25,26], which does not change
scoring. Disability as measured by the HAQ-DI repeatedly
has been correlated with mortality rates, progression of
aging, and health care resource utilization [25, 57, 135,
181]. For additional information regarding scoring and
analysis, please refer to to the ARAMIS website, http://ara-
mis.stanford.edu, and Bruce B and Fries JF, The Stanford
Health Assessment Questionnaire (HAQ): A Review of Its
History, Issues, Progress, and Documentation. J Rheuma-
tol. 2003;30(1):167–78.
The HAQ pain scale is designed to obtain data relative to
the presence or absence of arthritis-related pain and its
severity. The objective is to obtain information from
patients on how their pain has usually been over the past
week, even though pain may be reported to vary over the
course of a day or from day to day. Complete scoring
directions are available at the ARAMIS website, http://ara-
mis.stanford.edu.
Table 1: Translations and Cultural Adaptations of the Adult Health Assessment Questionnaire (HAQ) and the Childhood Health 
Assessment Questionnaire (CHAQ)
NOTE: References for independent translations are found in Bruce B, Fries JF. The Stanford health assessment questionnaire (HAQ): a review of its 
history, issues, progress, and documentation. J Rheumatol. 2003;30(1):167–78. Table adapted and used by permission of the Journal of 
Rheumatology.
Independent translations: 
HAQ: Arabic, Australian, Austrian, Chinese, Finnish, French (France), German, Italian, Korean, Netherlands, Norwegian, Portuguese (Brazil, Portu-
gal), Scandinavian (multiple languages), Scottish, Spanish (Mexican, Chilean European, Costa Rican, Argentinian), Swedish, Swiss, Thai, Turkish.
CHAQ: Austrian, Bulgarian, Croatian, Danish, Dutch, Czechoslovakian, English (British), Finnish, Belgian-Flemish, French (France), Georgian, Ger-
man, Greek, Hebrew, Hungarian, Italian, Latvian, Korean, Netherlands, Polish, Portuguese (Brazil), Russian, Serbian, Slovakian, Spanish (Argentinian, 
Castillian, Costa Rican, Mexican), Swiss-German and Swiss-French, Turkish.
Translations/adaptations available through the Health Outcomes Group (E-mail: HOG_USA@Compuserve.com):
Australian, Austrian, Belgian Dutch (Flemish), Belgian French, Canadian (French), Chinese (Cantonese [Hong Kong]), Croatian, Danish, English 
(Canadian, United Kingdom), Finnish, French (France), German (Germany, Switzerland), Greek, Israel (English), Hebrew, Italian, Lithuanian, Portu-
guese (Brazil, Portugal), Romanian, Singapore (English, Malay, Mandarin), Slovenian, So. Africa (Afrikaans, English), Spanish (Argentinian, Chilean, 
Columbian, Costa Rican, Guatemalan, Peruvian, Spain, United States, Venezuelan), Swedish, Turkish.
Translations/adaptations available through the MAPI Institute (website: http://www.mapi-research-inst.com):
Australian, Austrian (German), Belgian Dutch (Flemish), Belgian French (Walloon), Canadian (French), Czech Republic, Danish, Dutch, English 
(Canadian, India, New Zealand, United Kingdom), Finnish, French (France), German, Greek, Hebrew, Hungarian, Israel, Italian, Japanese, Norwe-
gian, Polish, Portuguese (Brazil), Russian, Slovak Republic, So. Africa (Afrikaans, English), Spanish (Argentinian, Costa Rican, Guatemalan, Mexican, 
Spain, Venezuelan), Swedish.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/20
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How are the HAQ-DI scores interpreted?
Scores of 0 to 1 are generally considered to represent mild
to moderate difficulty, 1 to 2 moderate to severe disabil-
ity, and 2 to 3 severe to very severe disability. Average
scores that have been reported in a population-based
study are 0.49, and in osteoarthritis and rheumatoid
arthritis patients are 0.8 and 1.2, respectively. For addi-
tional references regarding score interpretation, please see
Bruce B and Fries JF, The Stanford Health Assessment
Questionnaire (HAQ): A Review of Its History, Issues,
Progress, and Documentation. J Rheumatol.
2003;30(1):167–78.
Is the HAQ-DI responsive to change? What is a 
meaningful change for the HAQ-DI score?
The HAQ-DI is very responsive to change, and usually is
the most sensitive to change of the available outcome
measures. It is used in the overwhelming majority of stud-
ies of rheumatoid arthritis and recommended by the
United States Food and Drug Administration and the
American College of Rheumatology. Some investigators
have suggested that the Minimal Clinical Important Dif-
ference is 0.22; others have maintained that 0.10 or there-
abouts is clinically important. Additional references may
be found in Bruce and Fries, The Stanford Health Assess-
ment Questionnaire (HAQ): A Review of Its History,
Issues, Progress, and Documentation. J Rheumatol.
2003;30(1):167–78.
What is the availability and cost of using the 
HAQ?
The HAQ is copyrighted by Stanford University for the
purpose of insuring that it will be used unmodified to pre-
serve the validity of its results and contribute to standard-
ization of assessment across studies. However, it is
considered to be in the public domain, with the request
that users cite relevant HAQ articles(s) in their publica-
tions. There is no charge from Stanford for permission to
use the English version of the HAQ. However, other
groups that have independently translated the HAQ may
charge for their versions.
Who may I contact (Email, fax and phone) to obtain a 
copy of HAQ?




How can we obtain more information about the HAQ?
Please go to the ARAMIS website at http://aramis.stan-
ford.edu.
Conclusions
Collection of longitudinal patient outcome data, based on
the five patient-centered dimensions, is increasingly
standard in clinical trials, epidemiologic studies, and in
patient care, representing a major paradigm shift over the
past two decades. The HAQ has increased the credibility
and use of comprehensive measurement techniques
involving validated patient self-report and has led to a
new appreciation of outcome assessment. Outcome meas-
urement is rapidly increasing in use, and we anticipate
increased focus on a smaller number of instruments with
supplemental questions used for disease or study-specific
queries. We believe the HAQ to have appropriate
attributes to be among those considered for use as stand-
ard instruments.
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